New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
04:55 EDTBOTA, BOTA, BOTA, BOTA, IMGN, IMGN, IMGN, IMGN, ARRY, ARRY, ARRY, ARRY, OFIX, OFIX, OFIX, OFIX, CMN, CMN, CMN, CMN, MDCO, MDCO, MDCO, MDCO, TTHI, TTHI, TTHI, TTHI, INO, INO, INO, INO, CNAT, CNAT, CNAT, CNAT, Q, Q, Q, QJefferies to hold a conference
2014 Global Healthcare Conference to be held in New York on June 2-5.
News For BOTA;CNAT;INO;TTHI;MDCO;CMN;OFIX;ARRY;IMGN;Q From The Last 14 Days
Check below for free stories on BOTA;CNAT;INO;TTHI;MDCO;CMN;OFIX;ARRY;IMGN;Q the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
09:54 EDTARRYArray BioPharma management to meet with Jefferies
Subscribe for More Information
September 22, 2014
08:10 EDTINOInovio initiates phase I clinical trial in patients with aerodigestive cancers
Inovio announced it has initiated a phase I clinical trial in patients with aerodigestive cancers. The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106. This immunotherapy targets human papillomavirus type 6, which causes most aerodigestive cancers. This study is part of Inovio's strategy to broadly expand clinical development of its DNA-based immune therapy products to treat different HPV types and the many diseases they cause. It is a phase I, open label compassionate study enrolling patients with invasive cancer who have exhausted all other treatment options. The study will test Inovio's immunotherapy, INO-3106, alone or in combination with DNA-based IL-12, Inovio's proprietary immune activator, in subjects with HPV-6 associated aerodigestive malignancies. Successful results could open a path to pursuing an FDA orphan designation for aerodigestive cancers.
September 19, 2014
10:53 EDTINO Options with increasing implied volatility: ESI INO VALE AGNC
Subscribe for More Information
09:05 EDTIMGNImmunoGen discloses Chief Medical Officer James O'Leary's intention to leave
Subscribe for More Information
September 12, 2014
13:48 EDTARRYArray names Sandor Chief Medical Officer to replace Needle
Subscribe for More Information
12:12 EDTMDCOThe Medicines Co. to host conference call
Subscribe for More Information
September 11, 2014
18:15 EDTARRYArray BioPharma names Victor Sandor as Chief Medical Officer
Array BioPharma (ARRY) announced the appointment of Victor Sandor, M.D., as Chief Medical Officer. Prior to joining Array, Sandor was senior VP for Global Clinical Development at Incyte Corporation (INCY). Sandor will replace Array's prior Chief Medical Officer, Michael Needle, M.D., who is leaving the company to pursue other opportunities.
September 9, 2014
12:08 EDTINOOptions with increasing implied volatility
Subscribe for More Information
09:45 EDTIMGNImmunoGen management to meet with Leerink
Subscribe for More Information
08:59 EDTCNATConatus should be bought ahead of data, says JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use